Title Novartis launches rivastigmine patches for mild to moderately severe Alzheimer’s dementia
Date Published 22/10/2007
Reporter initials Hina
Reporter surname Radia
Reporter affiliation Hospital Pharmacist
Source Personal communication, Novartis Pharmaceuticals, 19 October 2007
Abstract Novartis Pharmaceuticals has announced the launch of rivastigmine (Exelon) patches licensed for the symptomatic treatment of mild to moderately severe Alzheimer’s dementia.
The following patch strengths are available:
• Exelon 4.6 mg/24 h; 30 patches – basic NHS cost = £83.84
• Exelon 9.5 mg/24 h; 30 patches – basic NHS cost = £83.84